Warfarin Withdrawal: Pharmacokinetic-Pharmacodynamic Considerations

Clinical Pharmacokinetics

Volumn 30, Issue 4, 1996, Pages 300-313

  Palareti, Gualtiero ^a   Legnani, Cristina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7; LIVER ENZYME; PLASMA PROTEIN; PROTEIN C; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG WITHDRAWAL; HUMAN; HYPERCOAGULABILITY; LIVER MICROSOME; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RACEMIC MIXTURE; REVIEW; STOMACH; THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; HUMANS; THROMBOEMBOLISM; WARFARIN;

EID: 0029879524     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630040-00003     Document Type: Article

References (87)

1. Cosgriff TM, Stuart W. Chronic anticoagulant therapy in recurrent embolism of cardial origin. Ann Intern Med 1953; 38: 278-87
2. Wright IS. Treatment of thromboembolic disease. JAMA 1960; 174: 1921-4
3. Loeliger EA, Broekmans AW. Drugs affecting blood clotting and fibrinolysis and haemostasis. In: Dukes MNG, editor. Meyler's side effects of drugs. New York: Elsevier Science Publishers, 1984
4. Stenflo J, Fernlund P, Egan W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 1974; 71: 2730-3
5. Nelsestuen GL, Zyktovicz TH, Howard JB. The mode of action of vitamin K: identification of gamma carboxyglutamic acid as a component of prothrombin. J Biol Chem 1974; 249: 6347-50
6. Nelsestuen GL. Role of gamma-carboxyglutamic acid: an unusual protein transition required for calcium-dependent binding of prothrombin to phospholipid. J Biol Chem 1976; 251: 5648-56
7. Borowski M, Furie BC, Bauminger S, et al. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid. J Biol Chem 1986; 261: 14969-75
8. Suttie JW, Preusch PC. Studies of the vitamin K-dependent carboxylase and vitamin K epoxide reductase in rat liver. Haemostasis 1986; 16: 193-215
9. Gardill SL, Suttie JW. Vitamin K epoxide and quinone reductase activities. Biochem Pharmacol 1990; 40: 1055-61
10. Wallin R, Hutson S. Vitamin K-dependent carboxylation: evidence that at least two microsomal dehydrogenases reduce vitamin K1 to support carboxylation. J Biol Chem 1982; 257: 1583-6
11. Vermeer C, Hamulyak K. Pathophysiology of vitamin K-deficiency and oral anticoagulants. Thromb Haemost 1991; 66: 153-9
12. Conly JM, Stein K. Quantitative and qualitative measurements of K vitamins in human intestinal contents. Am J Gastroenterol 1992; 87: 311-6
13. Department of Health. Report on health and social subjects, No. 41: dietary reference values for food energy and nutrients for the United Kingdom. London: HMSO, 1991
14. Suttie JW, Mummah-Schendel LL, Shah DV, et al. Vitamin K deficiency from dietary vitamin K restriction in humans. Am J Clin Nutr 1988; 47: 475-80
15. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978; 17: 1371-7
16. Bell RG. Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K-epoxide cycle. Fed Proc 1978; 37: 2599-604
17. Wallin R, Martin LF. Vitamin K dependent carboxylation and vitamin K metabolism in liver: effects of warfarin. J Clin Invest 1985; 76: 1879-84
18. Thijssen HHW, Baars LGM. Microsomal warfarin binding and vitamin K 2,3-epoxide reductase. Biochem Pharmacol 1989; 38: 1115-20
19. O'Reilly RA. Vitamin K and other oral anticoagulant drugs. Annu Rev Med 1976; 27: 245-9
20. Breckenridge AM. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hemalol 1978; 15: 19-26
21. Jahnchen E, Meinertz T, Gilfrich H, et al. The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies. Clin Pharmacol Ther 1976; 20: 342-9
22. Thijssen HHW, Baars LG. Active metabolites of acenocoumarol. Do they contribute to the therapeutic effect? Br J Clin Pharmacol 1983; 16: 491-6
23. Kelly JB, O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet 1979; 4: 1-15
24. Levine WG. Anticoagulant, antithrombotic and thrombotic drugs. In: Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. New York: MacMillan Inc., 1975: 1350-68
25. Thijssen HHW, Hamulyak K, Willigers H. 4-Hydroxycoumarin oral anticoagulants: pharmacokinetics-response relationship. Thromb Haemost 1988; 60: 35-8
26. Fiessinger JN, Vitoux JF, Roncato M, et al. Variations of prothrombin time, factor VII and protein C with a single daily dose of acenocoumarol. Haemostasis 1989; 19: 138-41
27. Breckenridge A, Orme M, Wesseling H, et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974; 15: 424-30
28. Lewis RJ, Trager WF, Chan KK, et al. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974; 53: 1607-17
29. Banfield C, O'Reilly RA, Chan E, et al. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br J Clin Pharmacol 1983; 16: 669-75
30. Toon S, Trager WF. Pharmacokinetic implications of stereo-selective changes in plasma protein binding: warfarin/sulphinpyrazone J Pharm Sci 1984; 73: 1671-3
31. O'Reilly RA, Aggeler PM, Leong LS. Studies on the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man. J Clin Invest 1963; 42: 1542-51
32. Breckenridge A, Orme M. Kinetics of warfarin absorption in man. Clin Pharmacol Ther 1973; 14: 955-61
33. Mosterd JJ, Thijssen HHW. The relationship between the vitamin-K cycle inhibition and the plasma anticoagulant response at steady-state S-warfarin conditions in the rat. J Pharmacol Exp Ther 1992; 260: 1081-5
34. Levy G, Cheung WK. Pharmacological consequences of warfarin-protein binding. In: Tillement JP, Lindenlaub E, editors. Protein binding and drug transport. New York: Shattauer Verlag, 1984
35. Thijssen HHW, Janssen YPG. Target-based warfarin pharmacokinetics in the rat: the link with the anticoagulant effect. J Pharmacol Exp Ther 1994; 270: 554-8
36. Thijssen HHW, Drittijreijnders MJ. Vitamin-K metabolism and vitamin K1 status in human liver samples - a search for interindividual differences in warfarin sensitivity. Br J Haematol 1993; 84: 681-5
37. Nagashima R, O'Reilly R, Levy G. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 1969; 10: 22-35
38. Levy G, Lai C, Yacobi A. Comparative pharmacokinetics of coumarin anticoagulants. 32: Interindividual differences in binding of warfarin and dicumarol in rat liver and implications for physiological pharmacokinetics modeling. J Pharm Sci 1978; 67: 229-33
39. Yacobi A, Udall JA, Levy G. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 1976; 19: 522-8
40. O'Reilly RA, Welling PG, Wagner JG. Pharmacokinetics of warfarin following intravenous administration to man. Thromb Diath Haemorrh 1971; 25: 178-85
41. Yacohi A, Udall JA, Levy G. Intra-subject variation of warfarin binding to protein in serum of patients with cardiovascular disease. Clin Pharmacol Ther 1976; 20: 300-5
42. Kelly JG, O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacol 1979; 4: 1-15
43. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974; 16: 348-54
44. Hallak HO, Wedlund PJ, Modi MW, et al. High clearance of (s)-warfarin in a warfarin-resistant subject. Br J Clin Pharmacol 1993; 35: 327-30
45. Chan KK, Lewis RJ, Trager WF. Absolute configurations of the four warfarin alcohols. J Med Chem 1972; 15 (12): 1265-70
46. Park BK. Warfarin: metabolism and mode of action. Biochem Pharmacol 1988; 37: 19-27
47. Chan E, McLachlan AJ, Pegg M, et al. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994; 37: 563-9
48. McAleer SD, Chrystyn H, Foondun AS. Measurement of the (R)- and (S)-isomers of warfarin in patients undergoing anticoagulant therapy. Chirality 1992; 4: 488-93
49. Shepherd AMM, Heswick DS, Moreland TA, et al. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 4: 315-20
50. Mungall DR, Ludden TM, Marshall J, et al. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 1985; 13: 213-27
51. Mehta R, Reilly JJ, Olson RE. Vitamin K therapy in severe liver disease. J Parent Enter Nutr 1991; 15: 350-3
52. Loeliger EA, Hensen A, Mattern MJ, et al. Behaviour of factors II, VII, IX and X in bleeding complications during long term treatment with coumarin. Thromb Diath Haemorrh 1964; 10: 278-81
53. Kazimer FJ, Spittell JA, Thompson JJ, et al. Effect of oral anticoagulants on factors VII, IX, X and II. Arch Intern Med 1965; 115: 667-73
54. Viganò S, Mannucci PM, Solinas S, et al. Early fall of protein C during short-term anticoagulant treatment [abstract]. Thromb Haemost 1983; 50: 986
55. Chan E, Aarons L, Serlin M, et al. Inter-relationship among individual vitamin K-dependent clotting factors at different levels of anticoagulation. Br J Clin Pharmacol 1987; 24: 621-5
56. Owren PA. Control of anticoagulant therapy. Arch Intern Med 1963; 111: 248-58
57. Winter JH, Douglas AS. Oral anticoagulants. Clin Haematol 1981; 10: 459-80
58. Paul B, Oxley A, Brigham K, et al. Factor II, VII, IX and X concentrations in patients receiving long term warfarin. J Clin Pathol 1987; 40: 94-8
59. Kumar S, Haigh JRM, Tate G, et al. Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance. Br J Haematol 1990; 74: 82-5
60. Poller L, Thomson J. Evidence for rebound hypercoagulability after stopping anticoagulants. Lancet 1964; II: 62-4
61. Poller L, Thomson J. Reduction of 'rebound' hypercoagulability by gradual withdrawal ('tailing off') of oral anticoagulants. BMJ 1965; 1: 1476-7
62. Cotton RC, Wade EG. Effect of sudden withdrawal of long-term anticoagulant therapy on the heparin resistance and plasma fibrinogen level. Clin Sci 1964; 26: 337-43
63. Harenberg J, Haas R, Zimmermann R. Plasma hypercoagulability after termination of oral anticoagulants. Thromb Res 1983; 29: 627-33
64. Johnsson H, Orinius E, Paul C. Fibrinopeptide A in patients with acute myocardial infarction. Thromb Res 1979; 16: 255-60
65. Harenberg J, Haas R, Zimmermann R. Measurement of fibrinopeptide A in patients treated with phenprocoumon. Thromb Haemost 1981; 45: 282-4
66. Schofield KP, Thomson JM, Poller L. Protein C response to induction and withdrawal of oral anticoagulant treatment. Clin Lab Haematol 1987; 9: 255-62
67. Grip L, Blomback M, Schulman S. Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients. Eur Heart J 1991; 12: 1225-33
68. Valles J, Aznar J, Santos T, et al. Platelet function in patients with chronic coronary heart disease on long-term anticoagulant therapy - effect of anticoagulant stopping. Haemostasis 1993; 23: 212-8
69. White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995; 122: 40-2
70. Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-21
71. Meade TW, Mellows S, Brozovie M, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; II: 533-7
72. Morrissey JH, Macik BG, Neuenschwander PF, et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44
73. Raskob GE, Durica SS, Morrissey JH, et al. Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood 1995; 85: 3034-9
74. Sakata T, Kario K, Matsuo T, et al. Suppression of plasma-activated factor VII levels by warfarin therapy. Arterioscler Thromb Vasc Biol 1995; 15: 241-6
75. Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants - a prospective study. Thromb Haemost 1994; 72: 222-6
76. Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 1990; 4: 25-40
77. Conway EM, Bauer KA, Barzegar S, et al. Suppression of haemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 1987; 80: 1535-44
78. Mannucci PM, Bottasso B, Tripodi A, et al. Prothrombin fragment 1+2 and intensity of treatment with oral anticoagulants [letter]. Thromb Haemost 1991; 66: 741
79. Takahashi H, Wada K, Satoh N, et al. Evaluation of oral anticoagulant therapy by measuring plasma prothrombin fragment 1+2. Blood Coagulant Fibrinol 1993; 4: 435-9
80. Palareti G, Legnani C, Frascaro M, et al. Factor VIII:C levels during oral anticoagulation and after its withdrawal. Thromb Haemost. In press
81. van Wersch JWJ. Non-vitamin K-dependent clotting factors during oral anticoagulant treatment. Blood Coagulat Fibrinol 1992; 3: 727-30
82. Koster T, Blann AD, Briët E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5
83. Bauer KA, Goodman TL, Kass BL, et al. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest 1985; 76: 826-36
84. Mannucci PM, Tripodi A, Bottasso B, et al. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost 1992; 67: 200-2
85. Szczklik A, Dropinski J, Radwan J, et al. Persistent generation of thrombin after acute myocardial infarction. Arterioscler Thromb 1992; 12: 548-53
86. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8
87. Hirsh J. Rebound hypercoagulability. Stroke 1982; 13: 527-37